The AB Biodisk product portfolio is said to be very complementary to bioMerieux’s culture media and automated Vitek range for antibiotic susceptibility testing. The addition of the Etest will bring patients and customers a high medical-value test result for critical infections and critical patient treatment, where a precise minimum inhibitory concentration valuation is needed.
The AB Biodisk product range will also be an asset for use in pharmaceutical companies’s new drug development, boosting bioMerieux’s theranostics business.
bioMerieux will commercialize the AB Biodisk’s products under the bioMerieux brand through its global network in 150 countries, expanding its international footprint.
Stephane Bancel, CEO of bioMerieux, said: “For the past 18 months, bioMerieux has been following an ambitious strategy in microbiology, building on our leadership position with an enhanced portfolio of innovative solutions to better serve our customers.”